Some limitations that must be addressed before advancing the targeting of PHOX2B in neuroblastoma treatment include the need for more selective inhibitors to avoid off-target effects (157), the potential for resistance mechanisms to develop (158), the variability in tumor responses (157), and the requirement for more comprehensive in vivo studies to assess long-term safety and efficacy (158). The gene discussed is PHOX2B; the disease is neuroblastoma.